Wish to Participate in 25th Annual Needham Virtual Growth Conference

SAN FRANCISCO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- ContextLogic Inc. (d/b/a Wish) (NASDAQ: WISH), one of the world’s largest mobile ecommerce platforms, today announced that its management team plans to participate in the 25th Annual Needham Virtual Growth Conference on Thursday, January 12, 2023.

• Event: 25th Annual Needham Virtual Growth Conference
• Date: Thursday, January 12, 2023
• Fireside Chat: 1:30 PM ET

Portfolio managers and analysts who wish to request a meeting should contact their sales representative at Needham. A live webcast of the fireside chat presentation can be accessed by selecting “Investor Calendar” under the “News & Events” section of the Wish website at https://ir.wish.com. A replay of the webcast will be archived following the presentation in the “Investor Calendar” section.

About WishWish brings an affordable and entertaining shopping experience to millions of consumers around the world. Since our founding in San Francisco in 2010, we have become one of the largest global ecommerce platforms, connecting millions of value-conscious consumers to merchants all over the world. Wish combines technology and data science capabilities and an innovative discovery-based mobile shopping experience to create a highly-visual, entertaining, and personalized shopping experience for its users. For more information about the company or to download the Wish mobile app, visit www.wish.com or follow @Wish on Facebook, Instagram and TikTok or @WishShopping on Twitter and YouTube.

Investor contact:Ralph Fong, Wish[email protected]

Media contact:Carys Comerford-Green, Wish[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a97ffd0a-06c0-4deb-9f63-8ea02f9ef948

You May Also Be Interested In

• Publicis Groupe: First Half 2026 Results
• Nokia to publish second-quarter and half-year 2026 financial report on 23 July 2026
• Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma